Transgene operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Transgene with three other
pharmaceutical manufacturers in Europe:
Biomed Lublin Wytwornia Surowic I Szczepionek SA
sales of 36.34 million Polish New Zlotys [US$9.97 million]
of which 76%
was Traditional Segment),
(6.50 million Euro [US$7.58 million]
Co Don AG
based in Germany
(5.60 million Euro [US$6.52 million]
of which 100%
was Product sales).
During the year ended December of 2016, sales at
Transgene were 8.73 million Euro (US$10.17 million).
decrease of 8.8%
versus 2015, when the company's sales were 9.57 million Euro.
Contributing to the drop in overall sales was the 47.3% decline
in Research and Development Subsidies, from 245,000.00 Euro to 129,000.00 Euro.
There were also decreases in sales in
Research and Development Tax Credit (down 20.4% to 6.25 million Euro)
Bio-Production and Cooperations (down 31.3% to 548,000.00 Euro)
However, these declines were partially offset by the increase in sales of
Royalties and Licenses (up 169.6% to 1.80 million Euro)